RARE insider filings
Ultragenyx Pharmaceutical Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-19. Screen RARE transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings by 2 insiders — 8,510 shares, $127,561 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 7,066 shares @ $15.27 ($107,898) by Horn Howard, filed 2026-10-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Horn Howard — Chief Financial Officer | 1 | — | 1 leg · 7,066 sh · $107,898 | — |
| Huizenga Theodore Alan — SVP, Chief Accounting Officer | 2 | — | 2 legs · 1,444 sh · $19,663 | — |
Recent insider filings — Ultragenyx Pharmaceutical Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-19 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 7,066 @ $15.27 | EDGAR |
| 2026-09-15 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Sale (S): 1,283 @ $13.57 | EDGAR |
| 2026-09-08 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Sale (S): 161 @ $13.99 | EDGAR |
| 2026-08-04 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,696 @ $24.92 | EDGAR |
| 2026-08-04 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Sale (S): 1,900 @ $24.92 | EDGAR |
| 2026-07-06 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,698 @ $33.13 | EDGAR |
| 2026-06-15 | 4 | Sanders Corazon (Corsee) D. — Director | Sale (S): 2,000 @ $25.05 | EDGAR |
| 2026-06-15 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Sale (S): 1,899 @ $24.62 | EDGAR |
| 2026-06-01 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,653 @ $23.77 | EDGAR |
| 2026-05-18 | 4 | Ray Amrit — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Sanders Corazon (Corsee) D. — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | SULIMAN SHEHNAAZ — Director | Grant/award (A): 7,751 @ $0 · Sale (S): 5,740 @ $25.12 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Fust Matthew K — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | NARACHI MICHAEL — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Dunsire Deborah — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | WELCH DANIEL G — Director | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Crombez Eric — EVP and Chief Medical Officer | Sale (S): 344 @ $24.96 | EDGAR |
| 2026-05-04 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,683 @ $24.90 | EDGAR |
| 2026-04-24 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Grant/award (A): 20,241 @ $0 · Grant/award (A): 7,348 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Huang Dennis Karl — See Remarks | Grant/award (A): 23,116 @ $0 · Grant/award (A): 79,936 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Pinion John Richard — See Remarks | Grant/award (A): 23,116 @ $0 · Grant/award (A): 79,936 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Grant/award (A): 28,895 @ $0 · Grant/award (A): 49,960 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Harris Erik — EVP & Chief Commercial Officer | Grant/award (A): 28,895 @ $0 · Grant/award (A): 49,960 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Crombez Eric — EVP and Chief Medical Officer | Grant/award (A): 34,674 @ $0 · Grant/award (A): 59,952 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Horn Howard — Chief Financial Officer | Grant/award (A): 34,674 @ $0 · Grant/award (A): 59,952 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | KAKKIS EMIL D — President & CEO, Director | Grant/award (A): 76,745 @ $0 · Grant/award (A): 132,693 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 4,683 @ $20.97 | EDGAR |
| 2026-03-10 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Sale (S): 6,018 @ $21.40 · Sale (S): 3,508 @ $22.67 | EDGAR |
| 2026-03-03 | 4 | Pinion John Richard — See Remarks | Grant/award (A): 11,137 @ $0 · Sale (S): 10,029 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Harris Erik — EVP & Chief Commercial Officer | Grant/award (A): 11,643 @ $0 · Sale (S): 10,539 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Grant/award (A): 11,137 @ $0 · Sale (S): 8,135 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Tax withholding (F): 148 @ $23.39 · Sale (S): 1,632 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Horn Howard — Chief Financial Officer | Grant/award (A): 6,143 @ $0 · Sale (S): 5,290 @ $22.80 · Sale (S): 3,119 @ $22.54 · Sale (S): 1,635 @ $22.40 | EDGAR |
| 2026-03-03 | 4 | Crombez Eric — EVP and Chief Medical Officer | Grant/award (A): 11,643 @ $0 · Sale (S): 7,029 @ $22.80 | EDGAR |
| 2026-03-03 | 4 | Huang Dennis Karl — See Remarks | Grant/award (A): 11,137 @ $0 · Tax withholding (F): 999 @ $23.39 | EDGAR |
| 2026-03-03 | 4 | KAKKIS EMIL D — President & CEO, Director | Grant/award (A): 71,177 @ $0 · Sale (S): 54,404 @ $22.80 | EDGAR |
| 2026-02-03 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 3,061 @ $23.56 | EDGAR |
| 2026-01-05 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 3,150 @ $22.84 | EDGAR |
| 2025-12-30 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Sale (S): 85 @ $34.38 | EDGAR |
| 2025-12-11 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 3,081 @ $36.38 | EDGAR |
| 2025-10-14 | 4 | Horn Howard — Chief Financial Officer | Sale (S): 7,942 @ $31.51 | EDGAR |
| 2025-09-19 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Sale (S): 64 @ $29.17 | EDGAR |
| 2025-09-12 | 4 | Parschauer Karah Herdman — EVP and Chief Legal Officer | Sale (S): 2,450 @ $31.17 | EDGAR |
| 2025-09-08 | 4 | Huizenga Theodore Alan — SVP, Chief Accounting Officer | Sale (S): 84 @ $31.39 | EDGAR |
| 2025-06-23 | 4 | Sanders Corazon (Corsee) D. — Director | Sale (S): 2,405 @ $37.39 | EDGAR |
| 2025-05-19 | 4 | Ray Amrit — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Fust Matthew K — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | NARACHI MICHAEL — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Dunsire Deborah — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | WELCH DANIEL G — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
Recent 8-K events — Ultragenyx Pharmaceutical Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-03 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 2.02 — Results of Operations and Financial Condition ? 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-19 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-10-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-10-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-09-17 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-19 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-11 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RARE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs